Neuromodulation Options and Patient Selection for Parkinson's Disease.

Parkinson's disease; neuromodulation; deep brain stimulation; infusion therapies; lesioning.

Journal

Neurology India
ISSN: 1998-4022
Titre abrégé: Neurol India
Pays: India
ID NLM: 0042005

Informations de publication

Date de publication:
Historique:
entrez: 15 12 2020
pubmed: 16 12 2020
medline: 22 6 2021
Statut: ppublish

Résumé

Neuromodulation therapies, including deep brain stimulation (DBS) and pump therapies, are currently the standard of care for PD patients with advanced disease and motor complications that are difficult to control with medical management alone. The quest for alternate lesser invasive approaches led to the development of several novel therapies like intrajejunal levodopa infusions (IJLI), continuous subcutaneous apomorphine infusions (CSAI) and Magnetic Resonance guided Focused Ultrasound (MRgFUS) in recent years. To achieve good outcomes with any of these therapeutic modalities, careful patient selection, multidisciplinary evaluation and technical expertise are equally important. In this review, we will provide an overview of the neuromodulation strategies currently available for PD, emphasizing on patient selection and choosing among the various strategies.

Identifiants

pubmed: 33318347
pii: ni_2020_68_8_170_302473
doi: 10.4103/0028-3886.302473
doi:

Substances chimiques

Antiparkinson Agents 0
Levodopa 46627O600J

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

S170-S178

Déclaration de conflit d'intérêts

None

Auteurs

Roopa Rajan (R)

Department of Neurology, All India Institute of Medical Sciences, New Delhi, India.

Matej Skorvanek (M)

Department of Neurology, P. J. Safarik University; Department of Neurology, University Hospital of L. Pasteur, Kosice, Slovakia, USA.

Veronika Magocova (V)

Department of Neurology, P. J. Safarik University; Department of Neurology, University Hospital of L. Pasteur, Kosice, Slovakia, USA.

Junaid Siddiqui (J)

Department of Neurology, University of Missouri-School of Medicine, Columbia, MO, USA.

Omar A AlSinaidi (OA)

Department of Neurology, National Neuroscience Institute, King Fahad Medical City, Riyadh, Saudi Arabia.

Heba M Shinawi (HM)

Department of Neurology, National Neuroscience Institute, King Fahad Medical City, Riyadh, Saudi Arabia.

Fahd AlSubaie (F)

Department of Neurosurgery, National Neuroscience Institute, King Fahad Medical City, Riyadh, Saudi Arabia.

Najeeb AlOmar (N)

Department of Neurosurgery, National Neuroscience Institute, King Fahad Medical City, Riyadh, Saudi Arabia.

Milind Deogaonkar (M)

Department of Neurological Surgery, West Virginia University, Morgantown, WV, USA.

Jawad A Bajwa (JA)

Department of Neurology, National Neuroscience Institute, King Fahad Medical City, Riyadh, Saudi Arabia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH